Variant position: 344 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 933 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LEDES-YDGGAGAASAFAPPR SSPCASSTPVAVGDFPDCAYP
Gorilla LEDES-YDGGAGAASAFAPPR SSPSASSTPVAVGDFPDCAY
Chimpanzee LEDES-YDGGAGAXSAFAPPR SSPSASSTPVAVGDFPDCAY
Mouse LEGDS-YDGGATAQGPFAPPR GSPSAPSPPVPCGDFPDCTY
Rat LEGDS-YDGGAAAQVPFAPPR GSPSAPSPPVPCGDFPDCTY
Rabbit LEGES-YDGGAAAASPFVPQR GSPSASSTPVAGGDFPDCTY
Chicken LDVEAAYDGSA-----FGP-R SSPS-----VPAADLAEYGY
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 933 Progesterone receptor
1 – 566 Modulating, Pro-Rich
331 – 351 Disordered
345 – 345 Phosphoserine; by MAPK
1 – 594 Missing. In isoform 3.
17 – 635 Missing. In isoform 4.
344 – 344 S -> A. No interaction with SP1. No change in progestin-induced protein degradation; when associated with A-345. No change in sumoylation; when associated with A-294 and A-345.
345 – 345 S -> A. No change in progestin-induced protein degradation; when associated with A-344. No change in sumoylation; when associated with A-294 and A-344.
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.
Kastner P.; Krust A.; Turcotte B.; Stropp U.; Tora L.; Gronemeyer H.; Chambon P.;
EMBO J. 9:1603-1614(1990)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; ALTERNATIVE PROMOTER USAGE; VARIANT THR-344;
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-50; VAL-120; LEU-186; ARG-301; THR-344; SER-444; LEU-529; PRO-536; VAL-651 AND LEU-865;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.